Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog

Xenobiotica

Volumn 34, Issue 10, 2004, Pages 901-915

  McKillop, D ^a   Partridge, E A ^a   Hutchison, M ^a   Rhead, S A ^a   Parry, A C ^a   Bardsley, J ^a   Woodman, H M ^a   Swaisland, H C ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; M 295820; M 387783; M 523595; M 527301; M 537194; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; DRUG SENSITIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LUNG NON SMALL CELL CANCER; MALE; MASS SPECTROMETRY; NONHUMAN; PLASMA CLEARANCE; RADIOACTIVITY; RAT; SENSITIVITY ANALYSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; INJECTIONS, INTRAVENOUS; MALE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RATS; RATS, WISTAR; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEX FACTORS; SPECIES SPECIFICITY;

CANIS FAMILIARIS;

EID: 10644271617     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250400009189     Document Type: Article

References (27)

1. BOXENBAUM, H., 1980, Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. Journal of Pharmacokinetics and Biopharmaceutics, 8, 165-176.
2. CIARDIELLO, F. and TORTORA, G., 2002, Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opinion on Investigational Drugs, 11, 755-768.
3. COBLEIGH, M. A., VOGEL, C. L., TRIPATHY, D., ROBERT, N. J., SCHOLL, S., FEHRENBACHER, L., WOLTER, J. M., PATON, V., SHAK, S., LIEBERMAN, G. and SLAMON, D. J., 1999, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Journal of Clinical Oncology, 17, 2639-2648.
4. COLLINS, J. M., GRIESHABER, C. K. and CHABNER, B. A., 1990, Pharmacologically guided phase I clinical trials based upon preclinical drug development. Journal of the National Cancer Institute, 82, 1321-1326.
5. DI FIORE, P. P., PIERCE, J. H., KRAUS, M. H., SEGATTO, O., KING, C. R. and AARONSON, S. A., 1987, erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science, 237, 178-182.
6. ENNIS, B. W., LIPPMAN, M. E. and DICKSON, R. B., 1991, The EGF receptor system as a target for antitumor therapy. Cancer Investigation, 9, 553-562.
7. FONTANINI, G., VIGNATI, S., BIGINI, D., MUSSI, A., LUCCHI, H., ANGELETTI, C. A., PINGITORE, R., PEPE, S., BASOLO, F. and BEVILACQUA, G., 1995, Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. European Journal of Cancer, 31A, 178-183.
8. FUKUOKA, M., YANO, S., GIACCONE, G., TAMURA, T., NAKAGAWA, K., DOUILLARD, J. Y., NISHIWAKI, Y., VANSTEENKISTE, J., KUDOH, S., RISCHIN, D., EEK, R., HORAI, T., NODA, K., TAKATA, I., SMIT, E., AVERBUCH, S., MACLEOD, A., FEYEREISLOVA, A, DONG, R. P. and BASELGA, J., 2003, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology, 21, 2237-2246.
9. GULLICK, W. J., 1991, Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. British Medical Bulletin, 47, 87-98.
10. HERBST, R. S., MADDOX, A. M., ROTHENBERG, M. L., SMALL, E. J., RUBIN, E. H., BASELGA, J., ROJO, F., HONG, W. K., SWAISLAND, H., AVERBUCH, S. D., OCHS, J. and LORUSSO, P. M., 2002, Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. Journal of Clinical Oncology, 20, 3815-3825.
11. LEGRAVEREND, C., MODE, A., WESTIN, S., STROM, A., EGUCHI, H., ZAPHIROPOULOS, P. G. and GUSTAFSSON, J. A., 1992, Transcriptional regulation of rat P-450 2C gene subfamily members by the sexually dimorphic pattern of growth hormone secretion. Molecular Endocrinology, 6, 259-266.
12. LIN, J. H., CHIBA, M., CHEN, I. W., NISHIME, J. A. and VASTAG, K. J., 1996, Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence. Drug Metabolism and Disposition, 24, 1298-1306.
13. LYNCH, T. J., BELL, D. W., SORDELLA, R., GURUBHAGAVATULA, S., OKIMOTO, R. A., BRANNIGAN, B. W., HARRIS, P. L., HASERLAT, S. M., SUPKO, J. G., HALUSKA, F. G., LOUIS, D. N., CHRISTIANI, D. C., SETTLEMAN, J. and HABER, D. A., 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 350, 2129-2139.
14. McKILLOP, D., HUTCHISON, M., PARTRIDGE, E. A., BUSHBY, N., COOPER, C. M. F., CLARKSON-JONES, J. A., HERRON, W. and SWAISLAND, H. C., 2004, Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica (in press).
15. PAEZ, J. G., JANNE, P. A., LEE, J. C., TRACY, S., GREULICH, H., GABRIEL, S., HERMAN, P., KAYE, F. J., LINDEMAN, N., BOGGON, T. J., NAOKI, K., SASAKI, H., FUJII, Y., ECK, M. J., SELLERS, W. R., JOHNSON, B. E. and MEYERSON, M., 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-1500.
16. RANSON, M., HAMMOND, L. A., FERRY, D., KRIS, M., TULLO, A., MURRAY, P. I., MILLER, V., AVERBUCH, S., OCHS, J., MORRIS, C., FEYEREISLOVA, A., SWAISLAND, H. and ROWINSKY, E. K., 2002, ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. Journal of Clinical Oncology, 20, 2240-2250.
17. SAINSBURY, J. R., MALCOLM, A. J., APPLETON, D. R., FARNDON, J. R. and HARRIS, A. L., 1985, Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. Journal of Clinical Pathology, 38, 1225-1228.
18. SALOMON, D. S., BRANDT, R., CIARDIELLO, F. and NORMANNO, N., 1995, Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology-Hematology, 19, 183-232.
19. SIROTNAK, F. M., ZAKOWSKI, M. F., MILLER, V. A., SCHER, H. I. and KRIS, M. G., 2000, Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clinical Cancer Research, 6, 4885-4892.
20. SLAMON, D. J., CLARK, G. M., WONG, S. G., LEVIN, W. J., ULLRICH, A. and McGUIRE, W. L., 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-182.
21. THOMPSON, K. L., VINCENT, S. H., MILLER, R. R., COLLETTI, A. E., ALVARO, R. F., WALLACE, M. A., FEENEY, W. P. and CHIU, S. H., 1997, Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. Drug Metabolism and Disposition, 25, 1113-1118.
22. WAKELING, A. E., BARKER, A. J., DAVIES, D. H., BROWN, D. S., GREEN, L. R., CARTLIDGE, S. A. and WOODBURN, J. R., 1997, New targets for therapeutic attack. Endocrine-related Cancer, 4, 351-355.
23. WAKELING, A. E., GUY, S. P., WOODBURN, J. R., ASHTON, S. E., CURRY, B. J., BARKER, A. J. and GIBSON, K. H., 2002, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research, 62, 5749-5754.
24. WAXMAN, D. J., RAM, P. A., NOTANI, G., LEBLANC, G. A., ALBERTA, J. A., MORRISSEY, J. J. and SUNDSETH, S. S., 1990, Pituitary regulation of the male-specific steroid 6 beta-hydroxylase P-450 2a (gene product IIIA2) in adult rat liver. Suppressive influence of growth hormone and thyroxine acting at a pretranslational level. Molecular Endocrinology, 4, 447-454.
25. WOODBURN, J. R., 1999, The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacology and Therapeutics, 82, 241-250.
26. WORKMAN, P., BRUNTON, V. G. and ROBINS, D. J., 1992, Tyrosine kinase inhibitors. Seminars in Cancer Biology, 3, 369-381.
27. YARDEN, Y. and ULLRICH, A., 1988, Growth factor receptor tyrosine kinases. Annual Review of Biochemistry, 57, 443-478.